Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-422P is a pseudogene related to the U6 small nuclear RNA (snRNA) gene family. U6 snRNA is a highly conserved non-coding RNA essential for pre-mRNA splicing as a core component of the spliceosome in eukaryotic cells[1][3]. However, RNU6-422P itself is a duplicated or processed, non-functional sequence that does not produce functionally active RNA or protein and does not participate in splicing or any other defined biological process[2]. Pseudogenes like RNU6-422P are generally considered "genomic fossils"; they might retain some regulatory or transcriptional signatures, but are not considered functional targets for drug discovery, diagnostics, or therapeutic modulation[2]. There is no evidence that RNU6-422P is involved in disease, nor is it established as a biomarker or a molecule with therapeutic relevance. Context for Parent Molecule: The functional U6 small nuclear RNA (U6 snRNA) is critical for spliceosome function and pre-mRNA splicing in the nucleus[1][3]. While pseudogenes may occasionally have residual or regulatory effects, there is no current evidence that RNU6-422P possesses any such activity in humans[2]. Notes: - is_incorrect: true — Although the name refers to a real genomic locus, RNU6-422P is not a functional molecular target, but rather a pseudogene. The entry is correct in nomenclature but incorrect as a meaningful molecular or therapeutic target. - In vertebrates, including humans, multiple U6 pseudogenes exist; they are widespread and not considered druggable or relevant in clinical research[3]. - Structured information systems should not catalogue RNU6-422P as a legitimate disease or drug target; it should only be indexed as a non-functional pseudogene[2].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 422, pseudogene (RNU6-422P).